AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02133521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Study NCT02133521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Study NCT01711879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Details covered in arm description
Study NCT03764657 — intervention group
Intervention type: PROCEDURE
Intervention: In hot group 16 patients were treated by diathermy in Cold
Description: In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation
Study NCT03764657 — intervention group
Intervention type: PROCEDURE
Intervention: in Cold group 13 patients were treated by scalpel.
Description: the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife
Study NCT03937271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine tongue diagnosis
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
Study NCT04516096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
Study NCT01711879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Details covered in arm description
Study NCT03486717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Description: Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
Study NCT03505671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy
Study NCT03505671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT03505671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03505671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03937271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine pulse diagnosis
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
Study NCT03937271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
Study NCT04543253 — intervention group
Intervention type: OTHER
Intervention: MUSE biofeedback
Description: biofeedback through a headband
Study NCT01697527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT01697527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01697527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01697527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03937271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer's test
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
Study NCT01697527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Description: Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Study NCT01697527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
Study NCT01697527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo PET scan using \[18F\] FDG tracer
Study NCT01697527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fludeoxyglucose F18 PET
Study NCT00895479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graft placement surgery plus Trinam therapy
Description: Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery
Study NCT04145336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5cm 5-Fr PDS
Description: High-risk patients receive 5cm 5-Fr PDS
Study NCT04145336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7cm 5-Fr PDS
Description: High-risk patients receive 7cm 5-Fr PDS
Study NCT04145336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study NCT04145336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study NCT00824785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, oxaliplatin, capecitabine (EOX)
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
Study NCT00824785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EOX + panitumumab
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
Study NCT00336921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: Once daily
Study NCT00336921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT01275053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leptin
Description: 0.01mg/kg
Study NCT03990025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Linked Color Imaging
Description: Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
Study NCT03990025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: White Light Imaging
Description: White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
Study NCT03781960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
Study NCT03781960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
Study NCT01492309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Simulation
Description: Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
Study NCT01492309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
Study NCT03395171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
Study NCT01147731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: warfarin plus albiglutide
Description: A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
Study NCT01963117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiation therapy
Study NCT01588197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention/Distraction Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
Study NCT03505671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03505671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01242059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup
Study NCT01242059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup
Study NCT01242059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Served in a tomato soup
Study NCT00253500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg in a syringe
Study NCT00253500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: 120 MG q 2 weeks for 4 cycles
Study NCT00253500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: to remove small piece of cancer
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN101 3 mcg
Description: SUN-101 3 mcg bid
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 6.25 mcg
Description: SUN-101 6.25 mcg bid
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 12.5 mcg
Description: SUN-101 12.5 mcg bid
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg
Description: SUN-101 50 mcg bid
Study NCT02038829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium
Description: Aclidinium 400 mcg bid
Study NCT01151696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atarax (Hydroxyzine)
Description: One milligram per 10 kilogram, intramuscular use
Study NCT01151696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01588197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Quality/Severity Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
Study NCT01588197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
Study NCT03621969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exam and medical history
Description: This will be completed by a medical doctor on the research team
Study NCT03621969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessments
Description: One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
Study NCT03621969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Instruction and use of Device (RePlay)
Description: 1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home.
Study NCT01995370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study NCT01995370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study NCT01671085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SQ
Study NCT01671085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study NCT04542798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation
Study NCT04542798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation
Study NCT01392989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: Standard of care
Study NCT01392989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5 mg/kg, po
Study NCT01392989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg, oral
Study NCT01392989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 7.5 mg/kg, IV
Study NCT01392989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Study NCT00722436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 mg/kg load, then 10 mg/kg/hr
Study NCT00722436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Placebo
Study NCT04517526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT
Description: pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
Study NCT01818791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Making Proud Choices
Description: Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
Study NCT01818791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices
Description: Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
Study NCT01818791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices AND Getting To Outcomes
Description: In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors.
Study NCT00893113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Alfuzosin-matched One tablet once daily
Study NCT00893113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alfuzosin-matched One tablet once daily
Study NCT00893113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: 10 mg once daily
Study NCT00893113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alfuzosin
Description: 10 mg once daily
Study NCT00783705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT00783705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inositol
Description: Given orally
Study NCT00945750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily
Study NCT00945750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily
Study NCT02301585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising Test
Description: Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
Study NCT02301585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients are treated according to Surviving Sepsis Guidelines
Study NCT03654027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Docetaxel
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study NCT03654027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75mg/m2 IV d1)